keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation therapy

keyword
https://www.readbyqxmd.com/read/28931292/-salvage-lymph-node-dissection-in-radical-prostatectomy-failure-a-case-study
#1
N Marečková, M Staník, D Macík, J Doležel
Salvage lymph node dissection is a therapeutic option in patients with nodal-only recurrence after radical prostatectomy. Although this operation does not achieve a complete cure in the majority of cases, it can prolong survival and help postpone hormonal therapy in selected patients while being a relatively safe procedure. The authors describe a case study of a radical prostatectomy patient with radiologically proven recurrence of prostate cancer limited to an internal iliac node. He underwent salvage lymph node dissection with a complete biochemical response...
2017: Rozhledy V Chirurgii: Měsíčník Československé Chirurgické Společnosti
https://www.readbyqxmd.com/read/28930493/effect-of-comorbidity-on-prostate-cancer-specific-mortality-a-prospective-observational-study
#2
Prabhakar Rajan, Prasanna Sooriakumaran, Tommy Nyberg, Olof Akre, Stefan Carlsson, Lars Egevad, Gunnar Steineck, N Peter Wiklund
Purpose To determine the effect of comorbidity on prostate cancer (PCa)-specific mortality across treatment types. Patients and Methods These are the results of a population-based observational study in Sweden from 1998 to 2012 of 118,543 men who were diagnosed with PCa with a median follow-up of 8.3 years (interquartile range, 5.2 to 11.5 years) until death from PCa or other causes. Patients were categorized by patient characteristics (marital status, educational level) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stage) and by treatment type (radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and watchful waiting)...
September 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28925899/effect-of-androgen-deprivation-therapy-adt-on-bone-health-status-in-men-with-prostate-cancer
#3
Nur Vaizura Mohamad, Ima Nirwana Soelaiman, Kok Yong Chin
Backgraoung and Objective: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer. DISCUSSION: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer...
September 18, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/28924967/postoperative-radiotherapy-for-prostate-cancer-the-sooner-the-better-and-potential-to-reduce-toxicity-even-further
#4
Paolo Borghetti, Luigi Spiazzi, Claudia Cozzaglio, Sara Pedretti, Bruno Caraffini, Luca Triggiani, Diana Greco, Lilia Bardoscia, Fernando Barbera, Michela Buglione, Stefano Maria Magrini
PURPOSE: To evaluate biochemical relapse-free survival (bRFS), overall survival (OS), late rectal and bladder toxicities in a retrospective single institution series, also applying an in-house software for biological dose calculation. METHODS: 258 patients submitted to radiotherapy after prostatectomy were considered. Differences between groups were calculated using the log-rank test and the relevant clinical and therapeutic variables were considered for multivariate analysis...
September 18, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28921938/prostate-cancer-treatment-in-renal-transplant-recipients-a-systematic-review
#5
REVIEW
Giancarlo Marra, Ettore Dalmasso, Marco Angello, Stefania Munegato, Andrea Bosio, Omidreza Sedigh, Luigi Biancone, Paolo Gontero
BACKGROUND: The majority of kidney transplants are performed in recipients (RTR) over 50; simultaneously their life expectancy is improving. The increasing age and number of RTR is likely to be paralleled by an increase of prostate cancer (PCa) incidence. However, little is known on the optimal management of these patients who represent a therapeutic challenge due to medical and anatomical graft-related issues. METHODS: AMED, Medline and Embase were searched until November 17(th) , 2016 adhering to the PRISMA guidelines and the AMSTAR checklist to investigate oncological and functional outcomes of PCa treatment in RTR...
September 18, 2017: BJU International
https://www.readbyqxmd.com/read/28921820/systematic-review-and-network-meta-analysis-on-the-relative-efficacy-of-osteoporotic-medications-men-with-prostate-cancer-on-continuous-androgen-deprivation-therapy%C3%A2-to-reduce-risk-of-fragility-fractures
#6
REVIEW
Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan, Murray Krahn
BACKGROUND: Androgen deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This analysis evaluated the relative effectiveness of osteoporosis treatments using BMD as a surrogate endpoint for fragility fractures in men on continuous ADT. METHOD: We included randomized controlled trials studying bisphosphonates, denosumab, toremifene, and raloxifene in patients with non-metastatic prostate cancer on ADT for review...
September 18, 2017: BJU International
https://www.readbyqxmd.com/read/28921785/cancer-specific-mortality-of-high-risk-prostate-cancer-after-carbon-ion-radiotherapy-plus-long-term-androgen-deprivation-therapy
#7
Goro Kasuya, Hitoshi Ishikawa, Hiroshi Tsuji, Yasuo Haruyama, Gen Kobashi, Daniel K Ebner, Koichiro Akakura, Hiroyoshi Suzuki, Tomohiko Ichikawa, Jun Shimazaki, Hirokazu Makishima, Takuma Nomiya, Tadashi Kamada, Hirohiko Tsujii
The treatment outcomes of patients with high-risk localized prostate cancer (PC) after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT) were analyzed, and compared with those of other treatment modalities, focusing on PC-specific mortality (PCSM). A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding patients with T4 disease, 608 patients with high- or very-high-risk PC, according to the National Comprehensive Cancer Network classification system, who received CIRT with LTADT were evaluated...
September 16, 2017: Cancer Science
https://www.readbyqxmd.com/read/28917268/targeting-androgen-independent-pathways-new-chances-for-patients-with-prostate-cancer
#8
REVIEW
C Cattrini, E Zanardi, G Vallome, A Cavo, L Cerbone, A Di Meglio, C Fabbroni, M M Latocca, F Rizzo, C Messina, A Rubagotti, P Barboro, F Boccardo
Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer (PC). Most patients eventually progress to a condition known as castration-resistant prostate cancer (CRPC), characterized by lack of response to ADT. Although new androgen receptor signaling (ARS) inhibitors and chemotherapeutic agents have been introduced to overcome resistance to ADT, many patients progress because of primary or acquired resistance to these agents. This comprehensive review aims at exploring the mechanisms of resistance and progression of PC, with specific focus on alterations which lead to the activation of androgen receptor (AR)-independent pathways of survival...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28916652/lsd1-mediated-epigenetic-reprogramming-drives-cenpe-expression-and-prostate-cancer-progression
#9
Yi Liang, Musaddeque Ahmed, Haiyang Guo, Fraser Soares, Junjie T Hua, Shuai Gao, Catherine Lu, Christine Poon, Wanting Han, Jens Langstein, Muhammad B Ekram, Brian Li, Elai Davicioni, Mandeep Takhar, Nicholas Erho, R Jeffrey Karnes, Dianne Chadwick, Theodorus van der Kwast, Paul C Boutros, Cheryl H Arrowsmith, Felix Y Feng, Anthony Michael Joshua, Amina Zoubeidi, Changmeng Cai, Housheng H He
Androgen receptor (AR) signaling is a key driver of prostate cancer (PCa), and androgen-deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic disease. However, patients receiving ADT eventually develop incurable castration-resistant PCa (CRPC). Here we report that the chromatin modifier LSD1, an important regulator of AR transcriptional activity, undergoes epigenetic reprogramming in CRPC. LSD1 reprogramming in this setting activated a subset of cell cycle genes including CENPE, a centromere binding protein and mitotic kinesin...
September 15, 2017: Cancer Research
https://www.readbyqxmd.com/read/28916273/identification-of-recurrence-sites-following-post-prostatectomy-treatment-for-prostate-cancer-using-11-c-choline-positron-emission-tomography-and-multiparametric-pelvic-mri
#10
Avinash Nehra, William P Parker, Rimki Haloi, Sean S Park, Lance A Mynderse, Val J Lowe, Brian J Davis, J Fernando Quevedo, Geoffrey B Johnson, Eugene D Kwon, R Jeffrey Karnes
PURPOSE: To describe anatomic sites of recurrence among prostate cancer patients with biochemical recurrence following radical prostatectomy (RP) and postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT) using (11)C-Choline PET/CT and multiparametric-MRI. MATERIALS AND METHODS: RP patients evaluated with (11)C-Choline PET/CT and multiparametric-MRI following RT and/or ADT were evaluated for patterns of recurrence and clinicopathologic features...
September 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28905815/psa-time-to-nadir-as-a-prognostic-factor-of-first-line-docetaxel-treatment-in-castration-resistant-prostate-cancer-evidence-from-patients-in-northwestern-china
#11
Kai-Jie Wu, Xin-Qi Pei, Ge Tian, Da-Peng Wu, Jin-Hai Fan, Yu-Mei Jiang, Da-Lin He
Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level ≥50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA...
September 12, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28905446/impact-of-five-tiered-gleason-grade-groups-on-prognostic-prediction-in-clinical-stage-t3-prostate-cancer-undergoing-high-dose-rate-brachytherapy
#12
Hideyasu Tsumura, Hiromichi Ishiyama, Ken-Ichi Tabata, Hiroki Katsumata, Momoko Kobayashi, Masaomi Ikeda, Shinji Kurosaka, Tetsuo Fujita, Masashi Kitano, Takefumi Satoh, Nobuyuki Yanagisawa, Kazushige Hayakawa, Masatsugu Iwamura
BACKGROUND: We evaluated a five-tiered Gleason grade groups arising from the 2014 International Society of Urological Pathology consensus conference on prognostic prediction in clinical stage T3a (extracapsular invasion) and T3b (seminal vesicle involvement) prostate cancer undergoing high-dose-rate brachytherapy (HDR-BT). METHODS: From November 2003 to December 2012, 283 patients with stage T3 prostate cancer received HDR-BT and external beam radiation therapy (EBRT) with long-term androgen deprivation therapy (ADT)...
September 14, 2017: Prostate
https://www.readbyqxmd.com/read/28905415/hyperactive-mtor-induces-neuroendocrine-differentiation-in-prostate-cancer-cell-with-concurrent-up-regulation-of-irf1
#13
Mayuko Kanayama, Toshiya Hayano, Michinori Koebis, Tatsuya Maeda, Yoko Tabe, Shigeo Horie, Atsu Aiba
BACKGROUND: Neuroendocrine-differentiated prostate cancer (NEPCa) is refractory to androgen deprivation therapy and shows a poor prognosis. The underlying mechanisms responsible for neuroendocrine differentiation (NED) are yet to be clarified. In this study, we investigated the role of mammalian target of rapamycin (mTOR) in NEPCa. METHODS: We utilized a gain-of-function analysis by establishing a human PCa LNCaP stable line that expresses hyperactive mTOR (LNCaP-mTOR)...
September 14, 2017: Prostate
https://www.readbyqxmd.com/read/28903374/resveratrol-enhances-polyubiquitination-mediated-arv7-degradation-in-prostate-cancer-cells
#14
Sarah Wilson, Lucia Cavero, Dali Tong, Qiuli Liu, Kyla Geary, Nicholas Talamonti, Jing Xu, Junjiang Fu, Jun Jiang, Dianzheng Zhang
Although androgen deprivation therapy (ADT) serves as the primary treatment option for localized or metastatic prostate cancer, most cases eventually develop into castration-resistant prostate cancer (CRPC). However, androgen receptor (AR) continues to be functional in CRPC through various mechanisms, including the development of AR splicing variants, especially ARV7. Since it lacks the ligand binding domain but retains the intact DNA binding domain, ARV7 is constitutively active, which makes ARV7-positive prostate cancer responsive to neither abiraterone nor enzalutamide...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28901514/multimodal-actions-of-the-phytochemical-sulforaphane-suppress-both-ar-and-ar-v7-in-22rv1-cells-advocating-a-potent-pharmaceutical-combination-against-castration-resistant-prostate-cancer
#15
Namrata Khurana, Hogyoung Kim, Partha K Chandra, Sudha Talwar, Pankaj Sharma, Asim B Abdel-Mageed, Suresh C Sikka, Debasis Mondal
Prostate cancer (PCa) cells expressing full-length androgen receptor (AR-FL) are susceptible to androgen deprivation therapy (ADT). However, outgrowth of castration-resistant prostate cancer (CRPC) can occur due to the expression of constitutively active (ligand-independent) AR splice variants, particularly AR-V7. We previously demonstrated that sulforaphane (SFN), an isothiocyanate phytochemical, can decrease AR-FL levels in the PCa cell lines, LNCaP and C4-2B. Here, we examined the efficacy of SFN in targeting both AR-FL and AR-V7 in the CRPC cell line, CWR22Rv1 (22Rv1)...
August 30, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28901378/androgen-independent-lncap-cells-are-a-subline-of-lncap-cells-with-a-more-aggressive-phenotype-and-androgen-suppresses-their-growth-by-inducing-cell-cycle-arrest-at-the-g1%C3%A2-phase
#16
Pan Yu, Xiuzhi Duan, Yue Cheng, Chunhua Liu, Yuhua Chen, Weiwei Liu, Binbin Yin, Xuchu Wang, Zhihua Tao
Androgen deprivation therapy (ADT, surgical or chemical castration) is the mainstay treatment for metastatic prostate cancer (PCa); however, patients ineluctably relapse despite extremely low androgen levels. This evolution of PCa indicates its lethal progression. In this study, to mimic the traits of clinical PCa progression in vitro, we investigated the alterations in the cell biological characteristics in androgen-independent LNCaP cells (LNCaP-AI cells) compared with LNCaP cells. We also examined the effects of androgen on LNCaP and LNCaP-AI cell proliferation, androgen receptor (AR) expression and prostate-specific antigen (PSA) secretion...
September 7, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28893901/expression-of-pd-l1-in-hormone-na%C3%A3-ve-and-treated-prostate-cancer%C3%A2-patients-receiving-neoadjuvant%C3%A2-abiraterone-acetate-plus-prednisone-and-leuprolide
#17
Carla Calagua, Joshua Russo, Yue Sun, Rachel Schaefer, Rosina Lis, Zhenwei Zhang, Kathleen M Mahoney, Glenn J Bubley, Massimo Loda, Mary-Ellen Taplin, Steven P Balk, Huihui Ye
PURPOSE: Programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) blockade has been unsuccessful in prostate cancer (PCa), with poor immunogenicity and subsequent low PD-L1 expression in PCa being proposed as an explanation. However, recent studies indicate that a subset of PCa may express significant levels of PD-L1. Further, the androgen antagonist enzalutamide has been shown to up-regulate PD-L1 expression in PCa preclinical models. In this study, we evaluated the effect of neoadjuvant androgen deprivation therapy with abiraterone acetate plus prednisone and leuprolide (Neo-AAPL) on PD-L1 expression in PCa...
September 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28890245/efficacy-of-local-treatment-in-prostate-cancer-patients-with-clinically-pelvic-lymph-node-positive-disease-at-initial-diagnosis
#18
Thomas Seisen, Malte W Vetterlein, Patrick Karabon, Tarun Jindal, Akshay Sood, Luigi Nocera, Paul L Nguyen, Toni K Choueiri, Quoc-Dien Trinh, Mani Menon, Firas Abdollah
BACKGROUND: There is limited evidence supporting the use of local treatment (LT) for prostate cancer (PCa) patients with clinically pelvic lymph node-positive (cN1) disease. OBJECTIVE: To examine the efficacy of any form of LT±androgen deprivation therapy (ADT) in treating these individuals. DESIGN, SETTING, AND PARTICIPANTS: Using the National Cancer Database (2003-2011), we retrospectively identified 2967 individuals who received LT±ADT versus ADT alone for cN1 PCa...
September 7, 2017: European Urology
https://www.readbyqxmd.com/read/28886115/androgen-receptor-mediated-downregulation-of-microrna-221-and-222-in-castration-resistant-prostate-cancer
#19
Bin Gui, Chen-Lin Hsieh, Philip W Kantoff, Adam S Kibel, Li Jia
MicroRNAs (miRNAs) play important roles in cancer formation and progression by suppressing the production of key functional proteins at the post-transcriptional level in a sequence-specific manner. While differential expression of miRNAs is widely observed in cancers including prostate cancer (PCa), how these miRNAs are transcriptionally regulated is largely unknown. MiRNA-221 and miRNA-222 (miR-221/-222) are well-established oncogenes and overexpressed in breast, liver, pancreas, and lung cancer, but their expression and biological functions in PCa remain controversial...
2017: PloS One
https://www.readbyqxmd.com/read/28885333/rapidly-decreasing-level-of-prostate-specific-antigen-during-initial-androgen-deprivation-therapy-is-a-risk-factor-for-early-progression-to-castration-resistant-prostate-cancer-a-retrospective-study
#20
Guangjie Ji, Gang Song, Cong Huang, Shiming He, Liqun Zhou
To build a practical model for predicting the progression to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT).In all, 185 patients with prostate cancer who had received ADT as the primary therapy at our institution, from 2003 to 2014, were retrospectively enrolled. The following clinical variables were included in the analysis: age, clinical tumor, node, metastasis stage, Gleason score, risk groups of prostate cancer, prostate-specific antigen (PSA) at the initiation of ADT, PSA nadir after ADT, velocity of PSA decline, and the time to PSA nadir...
September 2017: Medicine (Baltimore)
keyword
keyword
58120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"